Nature Biotechnology, Published online: 16 December 2025; doi:10.1038/s41587-025-02924-1
Antibody–lectin chimeras (AbLecs) are an immunotherapy modality designed to bind and block glycans that contribute to immune suppression in cancer. AbLecs enhance antitumor immune responses both in vitro and in vivo, outperforming conventional antibody therapies, including approved cancer drugs.
Nature Biotechnology, Published online: 16 December 2025; doi:10.1038/s41587-025-02924-1Antibody–lectin chimeras (AbLecs) are an immunotherapy modality designed to bind and block glycans that contribute to immune suppression in cancer. AbLecs enhance antitumor immune responses both in vitro and in vivo, outperforming conventional antibody therapies, including approved cancer drugs. Read More
